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the medicine for the rare indication as distinct from the costs of the medicine for
the common disease.
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THE IMPACT OF FINANCIAL INCENTIVES ON ADHERENCE TO THERAPEUTIC
TREATMENT – INSIGHTS FROM AN ECONOMIC EXPERIMENT
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OBJECTIVES: The present study contributes to and augments the few economic
attempts to explain medical non-compliance. To this end, an “economic invest-
ment model” is suggested as conceptual framework reflecting the three phases
typically observed in medical treatments: “invasion”, “high compliance” and ex-
pected variations in compliance behavior. Based on this framework a cost-neutral
incentive scheme is developed; the impact of this incentive scheme on adherence
is evaluated.METHODS: Behavioral predictionswere empirically evaluated by sug-
gesting an experimental design that incorporates the key features of the concep-
tual framework. Computerized economic experiments with investment decisions
over 12 periodswere run (September - December 2011)with subjects recruited from
a pool of approx. 1800 students from different fields of study. 107 and 102 subjects
participated in the baseline and in the incentive treatment, respectively. Instruc-
tionswere context-free, thus no associationswithmedical treatments, pharmacies
etc. could emerge, possibly influencing subjects’ decisions in an uncontrolled way.
RESULTS: In the baseline treatment, adherence drops significantly closely before
(p0.03, McNemar, two-sided) and closely after (p0.016, McNemar, two-sided) a
reference point (period 6), which is constituted by costs imposed by the invasion
phase. In the incentive treatment only one significant drop from period 9 to 10
(p.016, McNemar, two-sided) exists. Especially in the last periods of the experi-
ment the proportion of subjects switching to non-adhere is weakly significantly
higher in the baseline treatment than in the treatment with monetary incentives
(p0.06, Wilcoxon, two-sided). CONCLUSIONS: Decisions predicted by behavioral
economic theories similar to those documented in other contexts are at play in this
experimental setup and explain why adherence switches to non-adherence at
some point. By using financial incentives this switching point is shifted towards
the end of the “therapeutic treatment”. Thus, adherence is observed over a longer
span compared to a design providing no financial incentives.
PHP17
NATION-WIDE SURVEY OF PATIENTS’ ATTITUDE TOWARD LOW PRICE
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OBJECTIVES: Large amounts of health care cost are spent on drugs in Korea, 29.6%
of total health care expenditure in 2009, and these amounts are continuously in-
creasing. To control spending on prescription drugs we had tried to adopt the
reference pricing system in 2001, but it failed due to patients’ negative perception
and shortage of infrastructure. Recently, it is estimated that the technical circum-
stances are prepared. Yet the public perception has not been checked whether it
has been changed or not. The aim of this study was to ascertain the patients’
willingness to exchange the prescribed drug for the cheaper one in order to predict
the acceptability of the reference price system.METHODS: Nation-wide telephone
interview survey was conducted for 1000 consumers from October 19 to 26, 2011.
RESULTS: Patients were asked whether they would exchange the drug prescribed
by their doctor for the cheaper drug of which therapeutic effectiveness is equiva-
lent. Of 1000 respondents, 647(64.7%) answered “Yes (I will exchange)”. And the
reasons of the 353 consumers who responded “No (I will not exchange)” are; their
trust in doctor’s judgment (56.1%, n198), little confidence in the equivalence be-
tween the medications (35.1%, n124), and there is no great difference among the
cost ofmedicines in general (8.8%, n31).CONCLUSIONS: Patients’ attitude toward
lower price drug has been changed for last 10 years in Korea. They would likely to
choose cheaper drugs if information of exchangeable drug options and prices is
given at the time of prescribing or dispensing. It means that reference price system
would be acceptable by patients and contribute to reduce the pharmaceutical ex-
penditure in Korea. In addition, providing physicians with incentives to encourage
prescribing low pricemedicines and restoring consumer confidence in equivalence
of therapeutic effect are required to improve the effectiveness of the system.
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OBJECTIVES: Potential savings from generic drugs has become a key issue among
Canadian policy makers, with public drug programs in many Canadian provinces
reducing the amount they are willing to pay for generic drugs. This analysis exam-
ines generic drug spending in Canada, and looks at future patent expiries to esti-
mate the potential for savings in coming years. METHODS: This study examined
wholesale purchase data from IMS Brogan’s Canadian Drug Store and Hospital
Purchases Audit for all Canadian provinces between October 2004 and September
2010. Health Canada’s Patent Register and Drug Product Database were used to
estimate future dates of generic entry. RESULTS: Between 2004-05 and 2009-10,
purchases of generic drugs grew at 15.0% per year, three times faster than pur-
chases of brand name drugs. This increased the generic share of the Canadian drug
market from 17.0% to 25.9%. Further increases in the generic share are expected as
drugs with patents expiring between 2010 and 2014 accounted for 38.2% of all
purchases of prescription drugs in Canada in 2009. Drugs with patents expiring
beyond 2014 accounted for only 8.2% of drug purchases. CONCLUSIONS: Findings
suggest that there is potential for significant savings arising from new generic
competition in the next few years. The magnitude of these savings will depend on
the degree to which policy changes impact generic prices. However, theremay less
opportunity in the longer term. This issue is compounded by uncertainty as to the
regulatory requirements, manufacturing processes and pricing for “generic” ver-
sions of biologics.
PHP19
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Carter C1, Haas S2, Gunnarsson C2, Martin S3
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH,
USA, 3Centocor Ortho Biotech Services, LLC, Horsham, PA, USA
OBJECTIVES: To report ustekinumab dosing patterns in a large United States (U.S.)
retrospective healthcare claims database. METHODS: Patients with ustekinumab
prescriptions between 9/25/2009 and 12/31/2010 (first claim set index date) and
continuous activity in the Source® LX database (6 months pre- and 6 months
post-index) were included. Patients with evidence of other biologics during usteki-
numab treatment were excluded. Dosing was evaluated for the first 5 prescription
fills. Dose changeswere assessed for subsequent doses post-index and classified as
“higher than”, “same as”, or “lower than” the initial dose. The dosing interval was
defined as days between consecutive fills. Biologic experience was defined as  1
claim for another biologic pre-index. RESULTS: A total of 473 patients were evalu-
ated (meanSD agewas 4912 years; 46.3% female). 64.7% (n306) of patientswere
bio-experienced, while 35.3% (n167) had no history of biologic use before usteki-
numab (bio-naïve). Initial doses of 45 mg were observed for 69.3% of bio-experi-
enced and 72.5% of bio-naïve patients. Initial doses of 90 mg were observed for
30.7% of bio-experienced and 27.5% of bio-naïve patients. Subsequent doses were
the same as or lower than the initial dose for the majority of all (92.2%-96.8%),
bio-experienced (91.6%-97.7%), and bio-naïve (90.2%-95.2%) patients at each fill.
Overall median/mean dosing interval was 28/34 days for the first to second fill.
Median/mean dosing intervals for subsequent fills spanned 86-88/85-89 days. Dos-
ing intervals were similar among bio-experienced and bio-naïve patients.
CONCLUSIONS: In this longitudinal study of ustekinumab utilization in a US
healthcare claims database, nearly three-quarters of ustekinumab users had prior
treatmentwith biologics. Over two-thirds of initial ustekinumab doseswere 45mg.
Most patients remained at or below their starting dose. Dosing intervals were con-
sistent with prescribing recommendations (approximately one month for first 2
doses, followed by quarterly intervals). Dosing patterns in bio-experienced and
bio-naïve patients were similar.
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OBJECTIVES: To identify factors associated with primary nonadherence [PNA].
METHODS: This retrospective cohort study identified all new prescriptionswritten in
an integrated health care system for 10 therapeutic drug groups over a three-month
period (12/1/2009 - 2/28/2010). Study drugs included: antiinfectives, analgesics, mi-
graine medications, antidiabetics, osteoporosis medications, cardiovascular agents,
antihyperlipidemics, antiasthmatics, antidepressants, and anticoagulants. PNA was
defined as the failure to fill a prescription within 14 days of when it was written.
Stepwise multivariable logistic regression was used to identify significant patient,
provider and prescription characteristics associated with PNA. RESULTS: A total of
569,095 new prescriptions were written for the study drugs of interest during the
study period. Across all drug groups, the PNA rate was 9.8%. PNA rates for individ-
ual drug groups varied and were highest for osteoporosis medications (22.4%) and
antihyperlipidemics (22.3%). Patients were more likely to be primary nonadherent
if they were black, were not prescribed any drug from the same therapeutic drug
group during the past year, or had certain baseline comorbidities. Also, patients
who received brand name or multiple concomitant prescriptions were more likely
to be primary nonadherent. In contrast, patientswhofilled at least one prescription
in the prior year, had dual insurance orMedicaid coverage, or had a prescription for
a symptomatic disease were more likely to fill their prescription. Patients who
received prescriptions written by emergency medicine, pediatrics, or urgent care
were less likely to be primary nonadherent. Factors associated with PNA were
mostly consistent across all drug groups, but the estimated direction and signifi-
cance of some factors, such as patient gender and age, depended on whether the
treatment was acute or chronic. CONCLUSIONS: These results may be used to
facilitate clinicians and payers in making informed decisions when designing and
implementing cost-effective patient interventions to improve overall adherence to
medications.
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COMPLEMENTARY AND ALTERNATIVE MEDICINE USE AMONG PEOPLE WITH
DISABILITIES: NHIS 2007 SURVEY
Vohra R, Pan XL, Sambamoorthi U
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OBJECTIVES: To compare rates of Complementary and AlternativeMedicine (CAM)
use among individuals with and without disabilities.METHODS:We used a cross-
sectional design. Our data source was the 2007 National Health Interview Survey
files and the Adult Complementary and AlternativeMedicine Supplement. Individ-
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uals who reported limitation in activities due to any condition were considered
having disability. Any use of CAM use in the past 12 months was derived from the
adult CAM supplement and based on 21 different types of self or practitioner-based
therapies. Our final study sample (N  23,175) consisted of adult respondents over
age 18 and who did not have any missing values for disability status or CAM.
Chi-square tests were performed to test significant group differences between dis-
ability status and any CAM use. Logistic regression was used to assess the associ-
ation between disability status and CAM use after controlling for demographic,
socio-economic, access to care, health status, and life-style risk factors. All analy-
ses adjusted for the complex survey design. RESULTS: Overall, 32% of the sample
respondents reported CAM use in the past 12 months. Nearly one-third (31%) re-
ported activity limitations. The rates of CAM use was significantly higher among
individuals with disability (38.9%) compared to those without disability (30.4%).
Results from logistic regression suggested that peoplewith a disabilitywere almost
2 times as likely to use CAM even after adjusting for other characteristics(AOR
1.96, 95%CI 1.75-2.18, p0.001).CONCLUSIONS: Individualswith disabilitieswere
more likely to use CAM use compared to individuals without disabilities. A plausi-
ble reason for greater use of CAM among individuals with disability could be due to
the failure of conventional therapies in treatment and alleviation of symptoms.
Future studies need to examine as to whether greater CAM use among those with
disability is related to failure of treatment with conventional therapies.
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EXPLORATION OF CLAIMS-BASED UTILIZATION MEASURES FOR DETECTING
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OBJECTIVES: To explore the ability of claims-based utilization measures – includ-
ing traditional adherence measures, a novel measure of overlapping days supply,
and measures of asymmetrical use within a population – to detect non-medical
prescription drug use.METHODS: Prescription claims from a large employer-based
administrative claims database (MarketScan) were used to evaluate drug utiliza-
tion during the first year after an index prescription for 6 classes of drugs with a
known abuse potential and 3 classes without. Population-level measures of tradi-
tional adherence metrics (i.e., MPR and PDC) and a novel measure of overlapping
days supply (MPR:PDC ratio) were calculated for all medications. Measures of
asymmetrical use within a population were evaluated with the Lorenz curve, rep-
resenting the total drug supply used by the heaviest 1%, 5% and 50% of all users.
Each measure was used to rank order (high to low) agents across and within
classes. The resulting lists were qualitatively compared on their ability to rank
order similar or dissimilar patterns. RESULTS: The study cohort included 6,840,355
patients, mean age 48.1 years, 56.5% female. The mean MPR for drugs with known
abuse potential (0.13-0.53) was lower than for drugs without (0.72-0.84). The MPR
and PDC ranking across drugs was consistent, but the MPR:PDC and Lorenz curve
ranking showed a different pattern. In addition, several abusable drugs had the
highest mean MPR:PDC ratios (i.e., 1.14 for morphine, 1.13 for oxycodone, 1.11 for
dextroamphetamine). Percent drug use by the heaviest users was also higher for
abusable drugs (e.g., Lorenz 1% of 29.1% for acetaminophenwith codeine, 21.5% for
acetaminophen with oxycodone, and 18.4% for oxycodone). CONCLUSIONS: Pa-
tients taking drugs with a known abuse potential exhibited different utilization
patterns compared to drugs without. Measures accounting for overlapping days
supply and asymmetrical drug use within a population may be better suited to
detecting non-medical prescription drug use.
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OBJECTIVES: To explore the use of generic medicines amongst elderly in Belgium.
Therefore, market shares by volume of generic medicines for the different ATC
drug classes are calculated. Possible savings of increased use of 20 generic medi-
cines, based on the top expenditures in the off-patent market in Belgium, are
calculated.METHODS:Data on the use ofmedicines in the elderly population were
derived from a regional community pharmacy database which collects data of
dispensed prescription medicines in a selection of Belgian public pharmacies. The
variables delivered were the name, the ATC-code, the number of packages sold in
2010, the average price and the defined daily dose. Savings were calculated using
weighted average price levels for both originator and generic medicines. Three
scenarios of potential savings were calculated: a 5%, 10% or 20% increase of generic
market shares of the selected medicines. RESULTS: The generic market share for
elderly in 2010 was 23.1%, while this was 23.7% for the total Belgian population in
2009. Generic market shares for the five most important ATC drug classes (A, B, C,
M and N) varied from 8.81% for class B to 63.70% for class A. Market shares of the 20
drugs used in the exercise varied from 1.11% to 96.32%. Increasingmarket shares of
generic medicines could generate savings varying from 1.80% (5% increase) to
6.39% (20% increase) of the public expenditure on originator medicines. In a situa-
tion where generic market shares would reach 95%, estimated savings could even
be 20.15% of the public expenditure on original medicines for this selection of
medicines. CONCLUSIONS: The full potential of generic medicines in the elderly
population has not yet been realized in Belgium. Additional incentives for physi-
cians, pharmacists and patients are needed as an increased use of generic medi-
cines by elderly could generate significant savings.
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OBJECTIVES: Due to barriers such as cost, regimen complexity and perceived inef-
ficacy, a substantial percentage of patients do not conform tomedical instructions.
Onsite health centers with onsite pharmacies may improvemedication adherence
through convenient, holistic and relatively inexpensive care. Accordingly, this
study sought to evaluate the influence of these onsite pharmacies on medication
adherence. METHODS: A retrospective analysis of electronic prescribing and
claims data was performed to assessmedication adherence among employees and
their dependents that received medications from an onsite health center’s phar-
macy compared with those that used an alternative site. Specifically, the medica-
tion possession ratio (MPR) was evaluated for patients who received medication
associatedwith treatment of asthma, depression, diabetes, hypertension or hyper-
lipidemia. In addition, a subanalysis of MPR among condition management partic-
ipants was performed. RESULTS: Overall, the MPR among patients who used the
onsite health center’s pharmacy was higher than among those who used an alter-
nate source: 54.8% versus 50.7%, respectively. In particular, the MPR was signifi-
cantly (P 0.002) greater for hypertension patients who used the onsite pharmacy
compared with those who did not. In general, the longitudinal analysis did not
demonstrate significant differences between groups across time, indicating that
medication adherence was relatively consistent over the study period. Across con-
ditions, medication adherence was significantly (P  0.001) higher among patients
who participated in conditionmanagement programs than among thosewhowere
not enrolled. CONCLUSIONS: Both the onsite health center’s pharmacy and condi-
tion management program participation positively impacted medication adher-
ence among employees and their dependents.
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DERIVING PATIENT CHRONIC DISEASE CONDITIONS FROM MEDICATION
UTILIZATION USING COMBINATION OF CLINICAL RULES AND LOGISTIC
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OBJECTIVES: Pharmacists are on the frontline of health care and have the ability to
provide direct patient care in the form of prescription counseling, medication ther-
apeutic management, and patient health and wellness education. While other
healthcare providers often have access to medical records and other forms of di-
agnosis data, pharmacists typically rely on prescription dispensing data. The ab-
sence of diagnosis information from prescriptions presents a limiting factor to the
care that can be provided. This study aims to evaluate the use of a clinical rules and
predictive models to improve patient chronic disease identification.METHODS: A
retrospective analysis was conducted using de-identified pharmacy and medical
claims data covering the period for years 2007 and 2008. Patient disease conditions
were derived from pharmacy claims using Medi-Span® drug indication database.
We compared the medication-derived disease conditions to ICD-9 diagnoses ob-
tained frommedical claims. Diagnoses evaluated were: diabetes mellitus, asthma/
COPD, rheumatoid arthritis, Parkinson’s disease, human immunodeficiency virus,
multiple sclerosis, and hyperlipidemia. Multivariate logistic regression models
were built to improve the accuracy of diagnosis identification. RESULTS: Therewas
good agreement betweenmedication-derived patient disease conditions andmed-
ical claims diagnosed conditionswhile variations existed among selected diseases.
When using the medication-derived patient disease condition indicator alone as
predicator in a logistic model, predictive power as expressed in the area under
curve (AUC) for all seven diseases ranged from 0.72 to 0.90. Adding age, gender,
number of therapeutic class and drug cost as predictors to themodels significantly
improved the AUC an average of 13%, and the seven diseases ranged from 0.83 to
0.94. CONCLUSIONS: Pharmacy claims data are reasonably accurate identifiers for
chronic disease conditions when underlying conditions require specific medica-
tion treatments. Combining patient demographic information and medication-
related covariates into logistics regression models can enhance ability to identify
patient conditions.
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MULTIMORBIDITY AND POLYPHARMACY
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OBJECTIVES: Polypharmacy, defined as concurrent use of six ormoremedications,
is a critical issue in individuals with multiple chronic physical conditions. The
objective of the study is to estimate the rates and types of drug use and hence
polypharmacy among individuals with multiple chronic physical conditions and
compare these to individuals without multimorbidity. We also examine the rela-
tionship between polypharmacy and various clusters of conditions to identify the
trends of polypharmacy in particular clusters of conditions. METHODS: Cross-
sectional analysis of 9259 individuals of age above 21, with at least one chronic
physical condition in the following clusters: cardio-metabolic consisting of diabe-
tes or heart disease or hypertension, respiratory consisting of chronic obstructive
pulmonary disease or asthma and musculoskeletal consisting of osteoarthritis or
rheumatoid arthritis or osteoporosis from the 2008Medical Expenditure Panel Sur-
vey (MEPS). Chi-square tests and multivariate logistic regressions were performed
to analyze the rates and types of drug use and hence polypharmacy among various
chronic clusters. All analysis accounted for the complex survey design of theMEPS.
A17V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
